Greg Verdine's Quest to Transform Cancer Treatment with Unconventional Drug Approaches

Chemical biologist Greg Verdine is on a mission to transform cancer treatment, focusing on the challenging task of finding therapies for so-called "undruggable" diseases. This journey took a poignant turn when he listened to a podcast featuring former U.S. Senator Ben Sasse, who shared his experience with advanced pancreatic cancer. Miraculously, an experimental drug, daraxonrasib, had significantly reduced his tumors, extending his survival beyond expectations. Verdine, who played a pivotal role in this breakthrough, couldn't help but reflect, “I did that.”

Daraxonrasib's impact has been profound, nearly doubling the overall survival time for pancreatic cancer patients—from approximately 6.7 months to 13.2 months. This offers precious additional time for patients like Sasse, who represent just a fraction of the 60,000 Americans diagnosed with pancreatic cancer each year. Verdine describes this advancement as “a chink in the armor of a very difficult cancer.” As discussions continue on how to further extend survival, such insights pave the way for future breakthroughs.

What sets daraxonrasib apart is a clever mechanism involving a molecular glue that facilitates the binding of two proteins that typically could not adhere. For decades, the KRAS protein, a notorious cancer driver, was deemed impossible to target pharmacologically. Verdine’s distinctive approach broke new ground by demonstrating that with innovative binding techniques, it was indeed possible.

Verdine's career is marked by a series of breakthroughs in drug development, a trajectory he attributes to lessons learned from a family tragedy. At just five years old, his father became paralyzed from the neck down following an accident, drastically altering the family's dynamics and approach to problem-solving. This experience instilled in Verdine a strong sense of improvisation—skills he later applied to his scientific endeavors.

Excelling academically, Verdine initially pursued English but soon found his calling in organic chemistry. His fascination with manipulating molecules drew him into the intersection of chemistry and biology during his graduate studies at Columbia University. Here, he uncovered the mechanisms of cancer treatments, propelling him toward a faculty position at Harvard in 1988.

During his tenure, Verdine confronted a significant hurdle in drug development: many human proteins were largely classified as “undruggable.” This conclusion stemmed from two main challenges: proteins residing inside cells and the absence of suitable binding sites for drugs. Verdine proposed a novel idea: creating minimalistic protein therapeutics composed of short chains of amino acids designed to navigate cell membranes and effectively target these proteins.

However, these chains demonstrated flexibility that hindered their efficacy. To resolve this, Verdine conceptualized the idea of using a chemical “staple” to maintain the necessary helical structure for successful cellular penetration and binding. This line of thinking was risky; the potential for failure loomed large. Lacking traditional funding support, Verdine turned to Harvard’s Blavatnik Biomedical Accelerator (BBA), which champions pioneering research in early-stage development.

Securing three grants totaling $450,000 from the BBA made a considerable difference. As Curtis Keith, the BBA’s Chief Scientific Officer, pointed out, small investments can dramatically catalyze development during the precarious early phases of new technologies. Verdine’s concept blossomed into a new technology known as stapled peptides, which ultimately refined and expanded his capabilities in pharmaceuticals.

This foundational research led to the creation of Parabilis, where Zolucatetide is emerging as a first-in-class anti-cancer therapeutic. Recently, the FDA granted it fast-track designation for the treatment of desmoid tumors, marking a significant milestone. Zolucatetide, building on Verdine's helicon technology, binds to beta-catenin—a previously regarded undruggable protein—and inhibits processes that stimulate the growth of numerous cancers.

A consistently impressive outcome from early clinical trials indicates that Zolucatetide has led to tumor reductions in every participant with desmoid tumors. In June 2026, coincidentally Verdine’s birthday, Parabilis launched an initial public offering that garnered a substantial $770.5 million from venture capital—evidence of the promise this research holds for the future.

As the prospects for Zolucatetide unfold, Keith asserts that it could emerge as one of the most vital therapeutics to evolve from Harvard in recent memory. Reflecting on his journey, Verdine emphasizes that nurturing unconventional ideas is vital for advancing medical science. He advocates for supporting audacious projects, declaring, “We should be funding crazy stuff, because the crazy stuff is what changes the world.”